Summary
Overview
Work History
Education
Skills
Accomplishments
Presentations
References
Affiliations
Certification
Quantum, Subatomic Particles, Universe, Evolution, Art, Music, Tennis, SciFi, R&D, BioTechnology
Additional Information
Languages
Websites
Timeline
fe
Dr. Robert Imani, MD, PhD

Dr. Robert Imani, MD, PhD

Senior Medical Director
South San Francisco,CA

Summary

Drug development expert in the healthcare sector, consistently delivering successful outcomes for midsize and boutique biotechnology firms, CROs, and large pharmaceutical companies. With a proven track record in leading clinical development programs, managed projects from preclinical stages through early, mid, and late-phase clinical trials.

Experienced with clinical oversight, strategic planning, and team leadership. Utilizes regulatory compliance knowledge to ensure high standards of patient care. Track record of fostering collaborative environments and driving impactful results. Experienced medical leader with proven track record in driving clinical excellence and operational efficiency. Skilled in strategic planning, regulatory compliance, and patient-centered care. Strong focus on team collaboration, adaptable to changing needs, and results-driven. Known for building reliable teams and delivering impactful healthcare solutions.

Overview

31
31
years of professional experience
1
1
Certification

Work History

Senior Medical Director

CRISPR Therapeutics
San Francisco, CA
2019 - Current
  • Led clinical development programs for multiple assets, providing CPD, clinical, medical, and scientific strategy
  • Spearheaded Targeted Protein Degradation (TPD) programs, targeting and degrading protein
  • Engaged with the US FDA, filed INDs, and initiated clinical studies
  • Reviewed material used by medical team as part of Medical Review Board standards.
  • Reviewed Statistical Analysis Plans (SAPs), including interim analysis plans, stopping rules, and randomization schemes, while assessing protocol amendments as needed
  • Directed medical oversight for key clinical programs
  • Led initiatives focused on individualized treatment regimens, biomarkers, and companion diagnostics
  • Reviewed interim data, assessed publications, and presented findings at clinical study sites and investigator meetings after site activation
  • Evaluated clinical trial patient recruitment, retention, protocol adherence, and data quality to ensure timely completion of trials, advancing programs to mid-stage clinical studies
  • Monitored recruitment progress, data collection, case narratives review, query resolution and data lock.
  • Conducted thorough risk assessments for various scenarios, implementing mitigation strategies as needed.
  • Developed strategic partnerships with key external stakeholders.
  • Improved patient outcomes managing CST and IIT & IST strategy.
  • In collaboration with cross function leads, reduced overall costs while maintaining high-quality standards by optimizing resource allocation and utilization within the departments.

Vice President, Drug Development

Sumitomo Pharma Co., Ltd
Marlborough, MA
2017 - 2019
  • Worked closely with operation, quality control, regulatory affairs departments
  • Assessed educational needs and developed strategies for internal/external trainings and engagements
  • Monitored patients in Phase I/II clinical trials as a core member of the clinical development and product safety teams
  • Trained study site staff, Monitored eligibility, Medical Monitoring, etc
  • Reviewed the final draft TFLs according to SAP, presented the data to the upper management
  • Prepared and finalized synopses of clinical study protocols, investigator brochures, regulatory documents, and related clinical documents
  • Immunotherapy, Small and large molecules, TA: Hematology, IO
  • Demonstrated strong organizational and time management skills while managing multiple projects.
  • Learned and adapted quickly to new drug application and FDA approval.

Executive Medical Director

AMGEN – ONYX, An AMGEN Subsidiary
South San Francisco, California
2012 - 2016
  • Managed all aspects of Clinical Development Programs at ONYX / AMGEN before and after M&A (Onyx became An AMGEN Subsidiary)
  • Managed cardiac toxicity associated with the Investigational Medicinal Product (IMP) during ODAC and after product approval
  • Launched 2 BTD products after accelerated FDA approval based on positive Phase 2 PFS data for KYPROLIS and BLYNCYTO
  • Led investigator meetings and lead site initiation visits with clinical trial investigators
  • Interacted with clinical investigators and thought leaders, Key Opinion Leaders (KoLs)
  • Ensured completion of pivotal study recruitment as designated monitor
  • Led the development of safety sections, including Reference Safety Information, in the Investigator Brochure
  • Contributed to the product launch Plan (PLP) based on robust overall survival data from phase 2 (PFS) & Phase 3 (OS) clinical studies
  • Developed, improved, and implemented processes for signal detection, signal management, and benefit-risk evaluation
  • Led label negotiation during accelerated approval activities for Blincyto (ALL) and Kyprolis (multiple myeloma)
  • Developed strategic plans and initiatives for the organization''s growth, ensuring long-term financial sustainability and operational excellence
  • Discussed potential subject eligibility and protocol deviations
  • Ensured completion of pivotal study recruitment as designated monitor
  • Participated in cross-functional monitoring of pivotal post-marketing trial data as a core member of the safety team
  • Translated findings from research and nonclinical studies into clinical development opportunities
  • Analyzed industry trends and tracked competitor activities to inform decision making.
  • Interacted with clinical investigators and thought leaders
  • Composed Study Synopsis as well as full protocols, investigator brochures, clinical study reports
  • Conducted investigator meetings and lead site initiation visits with clinical trial investigators
  • Developed and maintained relationships with KOLs to deliver high value presentations
  • Oversaw divisional marketing, advertising and new product development.
  • Facilitated knowledge exchange among peers through regular conferences, seminars, workshops, ultimately elevating the standard of care across the organization.
  • Mentored junior physicians and staff members, cultivating a culture of continuous learning and professional development within the organization.
  • Devised and presented business plans and forecasts to board of directors.
  • Represented organization at industry conferences and events.
  • Established and maintained strong relationships with key opinion leaders, investigators, and strategic partners.

Senior Medical Director

Abbott
San Francisco, California
2010 - 2012
  • Assumed roles and responsibilities of program lead for assigned projects
  • As a core member of clinical development team and product safety team, monitored study conduct of multiple mid and late-stage clinical trials
  • Represented the company sub-teams during scientific meetings and presentations
  • Filed NDA (ISS & ISE)
  • Composed clinical study synopsis and full protocols
  • Led mid/late-stage clinical development programs
  • Reviewed the SAP, including the interim analysis plan, stopping rules and randomization scheme
  • Reviewed and considered any protocol modifications
  • Composed CSRs of completed clinical studies
  • Attended and provided medical expertise and support for meetings with study investigators
  • Developed and managed relationships with key opinion leaders for clinical programs and patient enrollments
  • Interacted with FDA and international regulatory authorities
  • Led internal and external scientific communications
  • Developed and executed clinical development strategies and alignments
  • Led medical and scientific clinical development activities
  • Conducted investigator meetings (IM) and led site initiation visits with clinical trial investigators
  • Developed contingency plans, provided technical and strategic advice
  • Ensured queries were sent and subject was followed-up until event resolution
  • Led product life cycle management activities with Abbott affiliates in global level (sNDA)
  • Reviewed subject eligibility, I&E criteria, assessed protocol deviations
  • Evaluated incoming safety information, ICSR narrative and reporting of AE. Reviewed SAEs, SUSARs narratives, analyses of similar events
  • Joined cross-functional meetings and provided continuous support
  • Reviewed core documents and updated as needed
  • Chaired various committees to ensure effective decision-making among stakeholders.
  • Played an instrumental role in acquiring new business opportunities for the organization through targeted outreach initiatives.
  • Mentored junior physicians, fostering a culture of continued learning and professional growth.
  • Reviewed material used by medical team as part of Medical Review Board standards.
  • Conducted care strategy evaluations to identify areas requiring improvement.
  • Recruited and managed physicians and nurses for busy multi-disciplinary practice.
  • Aligned GPRD strategies
  • Led conduct of clinical trials, FDA Approval, Label negotiations and Timely Product Launches.

Associate Medical Director

Forest Pharmaceuticals, Now Allergan
Jersey City, New Jersey
01.2009 - 01.2010
  • TA: CNS, Women and Men’s health, Pain management, GI, Anti-infective
  • Assumed roles and responsibilities of program lead for assigned projects
  • Led co-development activities with ABP (Ironwood, Almirall, ClinicalData, and Cerexa Pharmaceuticals)
  • Monitored incoming safety information, Laboratory values, Narratives of reported AE and ICSRs
  • Performed day to day medical monitoring tasks for assigned products after FIH study initiation
  • Ensured subject enrolment continued as planned and study completion timely within allocated budget
  • Reviewed laboratory abnormalities, liver, kidney, lungs, gonads, brain, and other vital organs functions
  • Reviewed and updated core documents
  • Ensured completion of CRF, SAP
  • Completed review of TFLs, Reviewed patients’ narratives for CSRs
  • Composed CSRs of completed clinical studies and ensured timely sign off and submission of CSRs
  • Discussed study designs for early and mid-stage clinical trials
  • Composed clinical study synopsis and full protocols
  • Led cross-functional medical monitor meetings and ad-hoc meetings with business partners
  • Reviewed the SAP, including the interim analysis plan, stopping rules and randomization scheme
  • Reviewed and considered any protocol modifications
  • Monitored interim data as needed
  • Updated IB, clinical study protocols, ICFs
  • Performed Medical Monitoring tasks, Reviewed and ensured subject eligibility
  • SAE narrative review
  • Monitored patients who participated in Phase 2 and 3 clinical trials and registries
  • As a core member of clinical development team, monitored patients enrolled during Phase I a/b and 2 a/b studies
  • Reviewed subject eligibility, I&E criteria, assessed protocol deviations
  • Attended TC weekly and ad-hoc meetings with ABP medical monitor of the sponsor
  • Led cross-functional meetings and provided continuous support
  • Training of the staff and external teams for updates regarding Safety Excellence
  • Improved patient outcomes by developing and implementing innovative treatment protocols.
  • Spearheaded process improvements that resulted in increased efficiency within department operations.
  • Successfully negotiated client contract renewals
  • Supervised clinical staff, providing continuous professional development opportunities and training.

Medical Director, Program Lead

Neurocrine Biosciences
01.2007 - 01.2009
  • TA: Women and Men's Health, CNS
  • Led medical monitoring responsibilities for phase 1 and 2 clinical studies for GnRH antagonist programs
  • As a core member of clinical development team (CDT) and product safety team (PST), monitored patients enrolled during Phase I a/b and 2 a/b clinical trials for 2 assigned products
  • Composed protocols, investigator brochures, clinical study reports and reviewed clinical trial documents
  • Conducted investigator meetings and led site initiation visits with clinical trial investigators
  • Executed and deployed clinical development strategic plans
  • Developed contingency plans, provided technical and strategic advice
  • Evaluated incoming safety information, ICSR narrative and reporting of AE
  • Ensured clinical study timelines, milestones and budgets are met
  • Provided medical monitoring to multiple oncology clinical trials
  • Led project teams to design and implemented clinical studies
  • Reviewed SAEs, SUSARs narratives, analyses of similar events
  • Ensured queries were sent and subject was followed-up until event resolution
  • Worked in a team environment comprising clinical operations, biomarker specialists, CROs, and regulatory affairs
  • Translated findings from research and nonclinical studies into clinical development opportunities
  • Interacted with Key Opinion Leaders and clinical study sites (investigators and study coordinators)
  • Worked with internal regulatory affairs team and other ethical guidelines relevant to the industry
  • Scientists, business and commercial organizations in a cross functional matrix environment
  • Designed clinical studies, Composed Clinical Study Synopsis and full Protocols
  • Ensured timely study completion and data read/reported
  • Led co-development activities with ABP (Pfizer and Abbott)
  • Analyzed incoming safety information from phase 1 - 3 clinical studies
  • Ensured compliance

Associate Medical Director

OSI Pharmaceuticals, Now Takeda
01.2004 - 01.2007
  • Clinical Research and Development for all TKI programs
  • TA: Oncology, Solid tumors, Multiple Sclerosis, Ophthalmology, Women and Men's Health
  • Performed Medical Monitor tasks for the assigned products
  • Assumed roles and responsibilities of program lead for assigned projects
  • Reviewed subject eligibility, I&E criteria, assessed protocol deviations
  • As a core member of clinical development team monitored patients enrolled in Phase 1, 2, 3
  • Performed day to day medical monitoring tasks for assigned products after FIH study initiation
  • Ensured subject enrolment continued as planned and study completion timely within allocated budget
  • Reviewed laboratory abnormalities, liver, kidney, lungs, gonads, brain, and other vital organs functions
  • Reviewed core documents and updated as needed (i.e
  • IB, Protocol, RSI update which impacted ICF, Protocol and IB
  • Determined NOAEL (no-observed-adverse-effect level) or no-effect level (NOEL) in toxicology studies
  • Ensured completion of CRF, SAP, MMP, SMP and DMP and data listing templates
  • Composed CSRs of completed clinical studies
  • Composed clinical study protocols
  • Led cross-functional medical monitor meetings and ad-hoc meetings with business partners
  • Led co-development activities with ABP (EMD Serono, Genentech and ROCHE)
  • Reviewed the SAP, including the interim analysis plan, stopping rules and randomization scheme
  • Reviewed and considered any protocol modifications
  • Monitored interim data
  • Led Pre-IND negotiations and IND package submission activities of clients
  • Proposed study design, composed clinical study protocol and other core documents
  • Led reproductive, developmental, neurotoxicology, immunotoxicology activities, Reviewed ADME data
  • Assessed pre-clinical research and risk assessment activities using laboratory animals, human and animal cells in culture
  • Monitored patient recruitment, retention and follow-up, protocol adherence, and data quality and completeness
  • Led design, planning, and execution of clinical trials (i.e
  • Surrogate endpoints)
  • Evaluated incoming safety information, ICSR narrative and reporting of AE
  • Attended cross-functional meetings and provided continuous support
  • Reviewed SAEs, SUSARs narratives, analyses of similar event

Stanford University, School of Medicine, Fellowship, Silicon Genetics
01.2000 - 01.2003
  • Clinical Research and Development, REI & CNS Laboratories
  • TA: Oncology, Women and Men's Health, CNS
  • Preclinical, FIH and Phase 2 a, Phase 2b studies
  • Composed protocols, investigator brochures, clinical study reports and reviewed clinical trial documents
  • Reviewed subject eligibility, I&E criteria, assessed protocol deviations
  • Explained ICF to the patients (potential subjects) and ensured ICF signed prior to enrolment to the study
  • Monitored patients I&E criteria, safety, laboratory data and enrolment during Phase I a/b and 2 a/b studies
  • Conducted investigator meetings and led site initiation visits with clinical trial investigators
  • Executed and deployed clinical development strategic plans
  • Developed contingency plans, provided technical and strategic advice
  • Evaluated incoming safety information, ICSR narrative and reporting of AE
  • Experiment applying Affymetrix gene expression minding Tools in REI laboratory of Ob
  • Gyn department
  • Diagnostic, Predictive Testing Using Biomarkers
  • Affymetrix Prognostic Tests
  • Gene Expression Profiling
  • Published 3 articles
  • Some of the responsibilities included:
  • ELISA and RIA techniques, Hybridization, FISH, Westerns blots, PCR, and ICH
  • In vitro cell culture (fresh or post IVF granulose cells), PAPP-a and proMBP project
  • Conducted Pre-Clinical and Clinical Experiments applying Microarray technology
  • Reported global gene profiling in human endometrium during the window of implantation
  • Led Affymetrix gene expression analyses activities of the post-doctorate teams
  • Global gene profiling in human endometrium (endometriosis or PCOS)
  • Reviewed scientific publications as deputy editor
  • Published 3 articles in Molecular Targeted Therapy
  • Used Microarray technology
  • Genespring 4.1 (, and Minding Tool (Affymetrix, Inc., CA)

Research Fellow, Director

Daniel Den Hoed Cancer Center
Rotterdam
1994 - 2000
  • Medical Monitor
  • Clinical Research and Development
  • TA: Oncology, Solid tumors, Women and Men's Health
  • FIH and Phase 2 a, Phase 2b clinical trials sponsored by Serono, Organon, Ferring, and Akzo Nobel
  • Assumed medical monitoring responsibilities for phase 1 and 2 clinical studies, Systemic Therapies
  • Training in Molecular Targeted Therapy (MTT)
  • Assessed pre-clinical research and risk assessment activities using laboratory animals, human and animal cells in culture
  • Assessed the performance of the trial with respect to patient recruitment, retention, follow-up, and protocol adherence
  • Translational Medicine activities, preclinical to clinical transition activities, clinical development & operation preparations
  • Led Pre-IND negotiations and IND package submission activities of clients
  • Examined the cellular, biochemical and molecular processes underlying toxic responses
  • Led reproductive, developmental, neurotoxicology, immunotoxicology activities, Reviewed ADME data
  • Led design, planning, and execution of clinical trials (i.e
  • Surrogate endpoints)
  • Proposed study design, composed clinical study protocol and other core documents
  • Performed day to day medical monitoring tasks for assigned products after FIH study initiation
  • Reviewed laboratory abnormalities, liver, kidney, lungs, gonads, brain, and other vital organs functions
  • Oversaw the implementation, monitoring and conduct of phase I, II, III clinical trials
  • Assisted with preclinical experiments in molecular targeted therapy
  • Acted as spokesperson and senior scientist during interaction with IRB, agency, CRO, and Advisory boards
  • Published research findings in top-tier academic journals, contributing to the advancement of knowledge in the field.
  • Increased interdisciplinary collaboration by organizing workshops bringing together researchers from diverse backgrounds.
  • Conducted extensive literature reviews to identify research gaps, fostering new research directions.
  • Co-authored multiple articles demonstrating real-world impact of clinical and preclinical research.
  • Developed new statistical models for data analysis, improving accuracy of research results.
  • Negotiated favorable contracts with vendors for reduced costs and improved service quality.
  • Proactively identified potential risks and implemented mitigation strategies to minimize risk for sponsors studies.

Education

Distinguished expert in Oncology pathways modeling utilizing AI / ML, Adjunct Faculty -

UCSF

University Clinical Development Strategies and leadership in healthcare online course -

Harvard

Distinguished Oncologist hematologist Expert, Faculty

PhD -

Erasmus MC
Rotterdam, the Netherlands

Distinguished Endocrine, Biomarkers and Predictive Modeling Expert, Faculty

Hematology & Oncology Residency -

Daniel den Hoed Cancer Centre
Rotterdam, the Netherlands

MD -

Erasmus MC
Rotterdam, the Netherlands

M.D. - Immuno-oncology Drugs | Target Specific R&D | Molecular Targeted Therapy | Stem Cells | Rep.Medicine

Stanford University School of Medicine
Stanford, CA
12.2003

Skills

  • Clinical trial design and execution
  • Clinical development
  • Regulatory reporting
  • Case narrative writing
  • Medical monitoring
  • Cross-functional collaboration
  • Teamwork
  • Communication
  • Regulatory affairs
  • Drug development
  • Clinical operations
  • Safety monitoring
  • Data management
  • Protocol development
  • Risk assessment
  • Signal detection
  • Benefit-risk evaluation
  • Label negotiation
  • Project management
  • Biomarker development
  • Companion diagnostics
  • Translational medicine
  • Pharmacokinetics
  • Pharmacodynamics
  • Oncology
  • Immunology
  • Hematology
  • Dermatology
  • Allergy
  • Biotechnology
  • Biopharmaceuticals
  • Drug discovery
  • Clinical study design
  • Clinical study management
  • IND filings
  • NDA filings
  • Product approvals
  • Product launches
  • AI/ML in oncology pathways modeling

Accomplishments

  • Documented and resolved [Issue] which led to [Results].
  • Achieved [Result] by completing [Task] with accuracy and efficiency.
  • Achieved [Result] through effectively helping with [Task].
  • Collaborated with team of [Number] in the development of [Project name].
  • Supervised team of [Number] staff members.
  • Achieved [Result] by introducing [Software] for [Type] tasks.
  • Used Microsoft Excel to develop inventory tracking spreadsheets.
  • Resolved product issue through consumer testing.

Presentations

  • An Open-label, Long-term Safety Study of Linaclotide in Patients with Chronic Constipation or Irritable Bowel Syndrome with Constipation
  • Randomized, Double-Blind, Dose-Range-Finding, Phase 2 Study of Linaclotide Administered to Patients With IBS-C
  • Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients with Chronic Constipation
  • Active, not recruiting An Efficacy and Safety Study of NBI-56418 in Endometriosis Conditions: Endometriosis; Pain, Interventions: Drug: NBI-56418; Drug: NBI-56418; Drug: placebo
  • Recruiting Efficacy and Safety Study in Endometriosis With NBI-56418; Placebo and Active Controlled Condition: Endometriosis, Intervention: Drug: NBI-56418 or placebo tablet; leuprorelin or placebo injection
  • Active, not recruiting Safety and Efficacy Study of NBI-56418 in Endometriosis Condition: Endometriosis, Interventions: Drug: NBI-56418; Drug: depo-subQ provera 104
  • Completed Endometriosis Trial: Study of NBI-56418 in Endometriosis Condition: Endometriosis. Intervention: Drug: NBI-56418 (GnRH antagonist)
  • RADIANT: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Single-Agent Tarceva (Erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non–Small-Cell Lung Carcinoma Who Have EGFR- Positive Tumors by Either FISH or IHC
  • Randomized double blind Clinical trial to Evaluate 3 Dosages of Third Generation of Progestagen After 28 Days Administration in Healthy Postmenopausal Women
  • Multicenter Clinical Trial of the efficacy and tolerability of a novel desogestrel OAC
  • Imani, R et al, AACR 2016: Clinical pharmacokinetics and pharmacodynamics of ME- 401, an oral, potent and selective inhibitor of phosphatidylinositol 3-kinase, following single ascending dose administration to healthy volunteers.
  • A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb7195.Poster Discussion Session, ATS 2016, San Francisco, CA, Paul Foster and Robert Imani
  • Imani, R; D Thai-Cuarto; R Jimenez R, J Burke, R Kroll, C O’Brien. PETAL Study: Safety, Tolerability and effectiveness of Elagolix, an Oral GnRH antagonist for endometriosis.
  • American Society for Reproductive Medicine (ASRM) 2009, Atlanta, GA. poster presentation in 2009.
  • Imani, R; Jimenez, R.; Burke, J.; Akright, B.; Koltun, W.; O’Brien, C. Endometriosis Recruitment Methodology and Patient Baseline Characteristics in Clinical Trials. Endocrine Society for Human Reproductive Endocrinology (ESHRE), Amsterdam, the Netherlands. Submitted for oral or poster presentation in 2009.
  • O’Brien, C, Jimenez, Imani, R; R.; Burke, J.; Dmowski, WP. Elagolix, An Oral GnRH antagonist For Endometriosis, Has Minimal Impact On Bone Mineral Density. Endocrine Society's Annual Meeting (ENDO 09), Washington, DC, June 10-13, 2009. Accepted.
  • Imani, B; Prediction of chances to conceive in normogonadotropic oligo-amenorrheic infertile patients following clomiphene citrate induction of ovulation. Reinier de Graaf Symposium, Noordwijk, The Netherlands, 26-28 September 1996.
  • Imani, B; Predictive value of initial screening in patients with cycle abnormality and infertility. Fertility weekend of Dutch and Belgium gynecologists, Antwerp, Belgium, May 16-17, 1998.
  • Imani, B; Prediction of response (ovulation versus conception) in patients treated with clomiphene citrate. Presentation at EMCR, The Netherlands, September 29 1998.
  • Imani, B; Discrepancies in predictors of ovulation and conception following clomiphene citrate induction of ovulation in normogonadotropic oligo-amenorrheic infertility. 16th World Congress on Fertility and Sterility and the 54th Annual Meeting of the American Society for Reproductive Medicine, San Francisco, California, USA. October 3-9, 1998.
  • Imani, B; Prediction of chances to conceive in normogonadotropic oligo-amenorrheic infertile patients following ovulation induction modalities. Anno 2000 summer symposium, Rotterdam, The Netherlands, July 26 2000.
  • Symposia: Organon Symposium on Steroida; Contraception, B. Imani, Herjan Coelingh Bennink, Fauser BCJM
  • Ferring Symposium Program, July 1996, Auditorium 1. How to Categorize patients with multicystic ovaries, Fauser BCJM, Imani B, van Santbrink E.J.P
  • Predictors of Chances to Conceive in Ovulatory Patients during Clomiphene Citrate Induction of Ovulation in Normogonadotropic Oligoamenorrheic Infertility, Section of Reproductive Endocrinology and Fertility, Department of Obstetrics and Gynecology, Dijkzigt Academic Hospital and Erasmus University, Rotterdam, the Netherlands
  • High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2) FSH response–dose can be predicted in ovulation induction for norm gonadotropic an ovulatory infertility

References

Two references available upon request

Affiliations

  • ABC

Certification

  • Board Certified in Healthcare Management (BCHM) - American College of Healthcare Executives.
  • Certified Medical Manager (CMM) - Professional Association of Health Care Office Management.
  • Project Management Professional (PMP) – Project Management Institute.
  • Certified Risk Manager In Healthcare(CRMH)Global Risk Community.
  • Lean Six Sigma Green Belt Certification (LSSGB) – International Association for Six Sigma Certification.
  • Master Certified Health Education Specialist (MCHES) – National Commission for Health Education Credentialing.
  • Registered Health Information Administrator (RHIA) - American Health Information Management Association.
  • Health Care Compliance Certification Program Certificate Holder(HCCP)- Compliance Certification Board.
  • Certified Healthcare Facility Manager (CHFM) - American Hospital Association.
  • Certified Nursing Home Administrator (CNHA) – National Association of Long Term Care Administrator Boards.
  • Licensed Independent Clinical Social Worker(LICSW)State specific licensure boards.
  • Diplomate in Clinical Social Work(DCSW)American Board Of Examiners In Clinical Social Work.
  • Certified Professional in Healthcare Quality (CPHQ) - National Association for Healthcare Quality.
  • Certified Medical Practice Executive (CMPE) - American College of Medical Practice Executives.
  • Nurse Executive, Advanced-Board Certified (NEA-BC) - American Nurses Credentialing Center.
  • Fellow of the American College of Healthcare Executives (FACHE) - American College of Healthcare Executives.
  • Certified In Public Health(CPH)National Board Of Public Health Examiners.
  • Fellow in the American Academy of Project Management (FAAPM) - American Academy of Project Management.
  • [Name of Certification] [Issuing Organization] [Year Month]

Quantum, Subatomic Particles, Universe, Evolution, Art, Music, Tennis, SciFi, R&D, BioTechnology

ffhfjhffhjfh

Additional Information

ckhgddgjhdjgd

Languages

English
Native or Bilingual
Dutch
Native or Bilingual
Turkish
Full Professional
German
Limited Working
Russian
Limited Working
Farsi
Limited Working
French
Elementary

Timeline

Senior Medical Director

CRISPR Therapeutics
2019 - Current

Vice President, Drug Development

Sumitomo Pharma Co., Ltd
2017 - 2019

Executive Medical Director

AMGEN – ONYX, An AMGEN Subsidiary
2012 - 2016

Senior Medical Director

Abbott
2010 - 2012

Associate Medical Director

Forest Pharmaceuticals, Now Allergan
01.2009 - 01.2010

Medical Director, Program Lead

Neurocrine Biosciences
01.2007 - 01.2009

Associate Medical Director

OSI Pharmaceuticals, Now Takeda
01.2004 - 01.2007

Stanford University, School of Medicine, Fellowship, Silicon Genetics
01.2000 - 01.2003

Research Fellow, Director

Daniel Den Hoed Cancer Center
1994 - 2000

University Clinical Development Strategies and leadership in healthcare online course -

Harvard

Distinguished Oncologist hematologist Expert, Faculty

PhD -

Erasmus MC

Distinguished Endocrine, Biomarkers and Predictive Modeling Expert, Faculty

Hematology & Oncology Residency -

Daniel den Hoed Cancer Centre

MD -

Erasmus MC

M.D. - Immuno-oncology Drugs | Target Specific R&D | Molecular Targeted Therapy | Stem Cells | Rep.Medicine

Stanford University School of Medicine

Distinguished expert in Oncology pathways modeling utilizing AI / ML, Adjunct Faculty -

UCSF

Similar Profiles

CREATE PROFILE
Dr. Robert Imani, MD, PhDSenior Medical Director